Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 Earnings
Published . Updated .
This report does not map to a usual set of affected companies.
Directly affected
- ARGX Argenx Se-18.7% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that argenx SE belongs to, so it often moves with news about it.
- AMGN Amgen+15.1% 30d
Amgen is a peer of argenx SE in biological products, (no diagnostic substances); rivals often move on the same news.
- GILD Gilead Sciences+6.6% 19d
Gilead Sciences is a peer of argenx SE in biological products, (no diagnostic substances); rivals often move on the same news.
- MRNA Moderna+36.4% 30d
Moderna is a peer of argenx SE in biological products, (no diagnostic substances); rivals often move on the same news.
- RVMD Revolution Medicines
Revolution Medicines is a peer of argenx SE in biological products, (no diagnostic substances); rivals often move on the same news.
- BIIB Biogen+9.6% 30d
Biogen is a peer of argenx SE in biological products, (no diagnostic substances); rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ARGXNo price data for this ticker | — | — | — | — | — | — | — |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| AMGNNo price data for this ticker | — | — | — | — | — | — | — |
| GILDNo price data for this ticker | — | — | — | — | — | — | — |
| MRNANo price data for this ticker | — | — | — | — | — | — | — |
| RVMDNo price data for this ticker | — | — | — | — | — | — | — |
| BIIBNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 Earnings Yahoo Finance
Source: Yahoo Finance
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor bought Amgen (AMGN), worth $1,001 - $15,000 on 22 Sep 2026. That is 32 days before publication. Filed 1 Oct 2026. View the filing.
- Rep. David J. Taylor sold Amgen (AMGN), worth $1,001 - $15,000 on 26 Aug 2026. That is 59 days before publication. Filed 5 Sep 2026. View the filing.
- Sen. Sheldon Whitehouse sold Amgen (AMGN) (held by a spouse), worth $1,001 - $15,000 on 12 Aug 2026. That is 73 days before publication. Filed 2 Sep 2026. View the filing.
- Rep. Rohit Khanna sold Gilead Sciences (GILD) (held by a dependent child), worth $1,001 - $15,000 on 10 Aug 2026. That is 75 days before publication. Filed 4 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 30 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 57 days before publication. Filed 8 Oct 2026. View the filing.
- Scott A Kupor, an executive branch official, sold Revolution Medicines (RVMD), worth $1,001 - $15,000 on 30 Jul 2026. That is 86 days before publication. Filed 30 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Biogen (BIIB), worth $1,001 - $15,000 on 24 Sep 2026. That is 30 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Biogen (BIIB) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Biogen (BIIB), worth $1,001 - $15,000 on 18 Aug 2026. That is 67 days before publication. Filed 1 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100
“Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 Earnings” scores 12 out of 100. The score uses 1 sources.